Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis

Table 4 Results of hematological adverse events (grade > 3) of the included studies that evaluated bevacizumab plus chemotherapy in mCRC

	n	Anemia	Neutropenia	Febrile neutropenia	Thrombocytopenia
Regimens containing irinotecan with/without bevacizumab
Hurwitz 2004/2005 [14, 42] (AVF 2107)
IFL/Bev	393	NR	37.0 %	NR	NR
IFL/placebo	397	NR	31.1 %	NR	NR
Guan 2011 [24] (ARTIST)
IFL/Bev	141	4 %	33 %	2 %	3 %
IFL	70	1 %	19 %	2 %	4 %
Stathopoulos 2010 [44]
IFL/Bev	114	NR	NR	NR	NR
IFL	108	NR	NR	NR	NR
Regimens containing oxaliplatin with/without bevacizumab
Saltz/Cassidy 2008/2011 [45, 46] (NO16966)
XELOX or FOLFOX/Bev	694	NR	NR	NR	NR
XELOX or FOLFOX/placebo	675	NR	NR	NR	NR
Regimens containing oxaliplatin or irinotecan with/without bevacizumab
Passardi 2013/2015 [21, 23] (ITACA)
FOLFOX or FOLFIRI/Bev	176	1.1 %	39.6 %	0.6 %	2.3 %
FOLFOX or FOLFIRI	194	2.6 %	42.3 %	2.1 %	1.0 %
Regimens containing only 5-FU with/without bevacizumab
Kabinnavar 2003 [47] (AVF0780)
5-FU/LV/Bev (5 mg/kg)	35	NR	5.7 %	NR	NR
5-FU/LV/Bev (10 mg/kg)	32		3.1 %
5-FU/LV	35		2.85 %
Kabinnavar 2005 [48] (AVF2192)
5-FU/LV/Bev	100	NR	5 %	NR	NR
5-FU/LV	104	NR	7 %	NR	NR
Regimens containing only capecitabine with/without bevacizumab
Tebutt 2010 [40] (MAX)
Capecitabine/Bev	157	NR	0 %	2.5 %	0 %
Capecitabine	156	NR	1.3 %	1.9 %	0 %
Cunningham 2013 [22] (AVEX)
Capecitabine/Bev	134	NR	1 %	NR	NR
Capecitabine	136	NR	1 %	NR	NR

Abbreviations: mCRC metastatic colorectal cancer, Bev bevacizumab, IFL fluorouracil/leucovorin + irinotecan, FOLFOX bolus and infusional fluorouracil/leucovorin + oxaliplatin, XELOX oxaliplatin + capecitabine, NR not reported

ISSN: 1471-2407